2022
DOI: 10.2147/idr.s373773
|View full text |Cite
|
Sign up to set email alerts
|

Carbapenems versus Cephalosporin or Piperacillin-Tazobactam as Perioperative Antibiotic Prophylaxis in Liver Transplant Recipients with Model for End-Stage Liver Disease Scores of ≥30: A Retrospective Study in a Chinese Population

Abstract: Objective Perioperative prophylaxis, commonly with a third-generation cephalosporin plus ampicillin or piperacillin-tazobactam, is usually employed to prevent infections in liver transplantation (LT) recipients. Patients with a high Model for End-Stage Liver Disease (MELD) score have an increased infection risk after LT. However, whether carbapenems could be used as surgical prophylaxis in these high-risk patients remains unclear. Therefore, this study aimed at comparing the effectiveness of carba… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 22 publications
(28 reference statements)
0
1
0
Order By: Relevance
“…Secondly, broad-spectrum antibiotics, including carbapenems and third-generation cephalosporin, should be used prophylactically or in combination. 27 Cytomegalovirus is the most common type of viral infection in liver transplant recipients and prophylactic therapy with intravenous ganciclovir or oral valganciclovir should be given within 3 mo of liver transplantation. 28,29 The immunosuppressant dose should be reduced if the Epstein-Barr viral load stays high or continues to rise.…”
Section: Discussionmentioning
confidence: 99%
“…Secondly, broad-spectrum antibiotics, including carbapenems and third-generation cephalosporin, should be used prophylactically or in combination. 27 Cytomegalovirus is the most common type of viral infection in liver transplant recipients and prophylactic therapy with intravenous ganciclovir or oral valganciclovir should be given within 3 mo of liver transplantation. 28,29 The immunosuppressant dose should be reduced if the Epstein-Barr viral load stays high or continues to rise.…”
Section: Discussionmentioning
confidence: 99%